A recent study challenges the long-held belief that primary glomerular diseases are harmless in children and young adults. But here's the twist: these patients might experience a more rapid decline in kidney function than their older counterparts. This discovery is set to be unveiled at the ASN Kidney Week 2025, leaving many in the medical community intrigued and concerned.
Directly comparing the outcomes of adult and pediatric patients with primary glomerular diseases is a rare occurrence, especially for conditions like minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA nephropathy (IgAN). Researchers delved into the CureGN dataset, a treasure trove of longitudinal data on glomerular diseases. Surprisingly, they found that children and young adults had similar or even higher risks of adverse outcomes, including kidney failure, a ≥40% drop in estimated glomerular filtration rate (eGFR), or death, when compared to older adults.
And this is where it gets even more intriguing: pediatric patients with a biopsy-confirmed MCD showed a more rapid decline in eGFR than adult MCD patients. The steepest eGFR declines were observed in MN patients aged 13-17 years and FSGS and IgA nephropathy patients aged 18-44 years at the time of biopsy. Interestingly, for MCD, FSGS, and MN, the risk of progressing to kidney failure, death, or a ≥40% eGFR decline was consistent across different age groups. However, IgA nephropathy patients aged 6-12 years, 13-17 years, and 45-64 years had lower progression risks than those aged 18-44 years.
These findings shed light on a critical issue: young patients diagnosed with primary glomerular diseases through kidney biopsy are at a significant risk of kidney failure and may need dialysis or a transplant during their lifetime. The study authors emphasize the need for further research to understand the long-term impact and morbidity associated with these diseases when diagnosed early in life.
Margaret Helmuth, MS, the lead author from the University of Michigan, Ann Arbor, highlights the importance of this research. Co-author Chia-shi Wang, MD, MSc, from the Emory University School of Medicine, adds, "By including children in clinical trials for disease treatment, we can better protect them from these severe outcomes."
Study Title: Glomerular Disease Outcomes Across the Lifespan: Report of the Cure Glomerulonephropathy (CureGN) Research Consortium
Note: While we ensure the accuracy of the content, any medical information should be verified with healthcare professionals. Your questions may be shared with our partners, excluding personal details, and retained temporarily for quality assurance.
